Suppr超能文献

药物的心肌摄取与临床疗效。

Myocardial uptake of drugs and clinical effects.

作者信息

Horowitz J D, Powell A C

出版信息

Clin Pharmacokinet. 1986 Sep-Oct;11(5):354-71. doi: 10.2165/00003088-198611050-00002.

Abstract

The process of uptake of cardioactive drugs into the myocardium is a major determinant of the efficacy and potential toxicity of such agents. Evaluation of responses to anti-arrhythmic and positive inotropic agents is best performed with reference to their concentration in the myocardium, and the potential toxicity of drugs such as tricyclic antidepressants and anthracycline antineoplastics is likely to be related to peak myocardial drug concentrations. Although it has been appreciated for many years that even during long term drug administration the myocardial drug content may not be readily predictable on the basis of estimation of plasma drug concentrations, methodology for direct assessment of myocardial drug content has remained limited. The results of in vitro experiments, utilising tissue culture preparations of myocardial cells or isolated atria, have shed some light on the role of local factors as determinants of myocardial drug uptake. For many agents, attainment of maximal cardiac drug content in vitro is a very slow process (taking up to 3 hours), although maximal inotropic and electrophysiological effects may occur more rapidly. The prolonged time course of drug washout from these preparations also reflects their extensive and slow intracellular accumulation. Mechanical activity of the myocardium appears to accelerate drug uptake, particularly for otherwise slowly equilibrating agents, but the major determinant of the extent of drug uptake into isolated myocardial preparations is lipophilicity, perhaps reflecting the passage of drugs through the sarcolemma. In intact animals, assessment of myocardial drug content after acute drug administration has been performed utilising serial myocardial biopsy or sacrifice of animals. Studies in open-chested dogs suggest that acute accumulation of agents may be most closely predicted from the second compartment of a 3-compartment pharmacokinetic model, and that there is a variable correlation between changes in plasma and myocardial drug concentrations. For example, bretylium concentrations within the myocardium continue to increase for up to 6 hours after drug administration. Factors which may influence drug uptake into the myocardium in intact animals include ischaemia, which usually results in a delay in both drug uptake and subsequent clearance. This change can also be inferred from the time course of onset of antiarrhythmic drug effects in some models of myocardial ischaemia. Anoxia may also inhibit myocardial drug uptake.(ABSTRACT TRUNCATED AT 400 WORDS)

摘要

心脏活性药物摄取进入心肌的过程是此类药物疗效和潜在毒性的主要决定因素。评估抗心律失常药和正性肌力药的反应,最好参考它们在心肌中的浓度,而三环类抗抑郁药和蒽环类抗肿瘤药等药物的潜在毒性可能与心肌药物峰值浓度有关。尽管多年来人们已经认识到,即使在长期给药期间,基于血浆药物浓度估计也可能难以准确预测心肌药物含量,但直接评估心肌药物含量的方法仍然有限。利用心肌细胞或离体心房的组织培养制剂进行的体外实验结果,为局部因素作为心肌药物摄取决定因素的作用提供了一些线索。对于许多药物来说,在体外达到最大心脏药物含量是一个非常缓慢的过程(长达3小时),尽管最大正性肌力和电生理效应可能出现得更快。这些制剂中药物洗脱的时间过程延长也反映了它们在细胞内广泛而缓慢的积累。心肌的机械活动似乎会加速药物摄取,特别是对于原本平衡缓慢的药物,但药物摄取到离体心肌制剂中的程度的主要决定因素是亲脂性,这可能反映了药物通过肌膜 的过程。在完整动物中,急性给药后通过连续心肌活检或处死动物来评估心肌药物含量。对开胸狗的研究表明,药物的急性蓄积可能最能通过三室药代动力学模型的第二室来密切预测,并且血浆和心肌药物浓度的变化之间存在可变的相关性。例如,给药后心肌内的溴苄铵浓度在长达6小时内持续升高。在完整动物中,可能影响药物摄取到心肌的因素包括缺血,这通常会导致药物摄取和随后清除的延迟。这种变化也可以从一些心肌缺血模型中抗心律失常药物作用的起效时间过程中推断出来。缺氧也可能抑制心肌药物摄取。(摘要截选至400字)

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验